乳酸钠治疗对急性脑损伤患者颅内压和脑代谢的影响:一项系统评价
该系统评价纳入12项临床前和12项临床研究,评估外源性乳酸钠在急性脑损伤(包括创伤性脑损伤、缺血性卒中、心脏骤停)中的效果。多数模型中乳酸钠能降低颅内压,临床环境中至少与甘露醇或高渗盐水同样有效和安全,部分研究报告全身血流动力学耐受性更好。代谢数据显示损伤脑组织可摄取和氧化乳酸,但代谢获益不一致,取决于氧化代谢保留、基线代谢状态、时机和剂量。功能结局数据有限,对有意义功能结局的影响仍不确定,需针对性临床试验进一步研究。
要点
- 在多数模型中,乳酸钠能有效降低颅内压;临床环境中至少与甘露醇或高渗盐水同样有效且安全。
- 部分研究报告乳酸钠相比传统渗透疗法全身血流动力学耐受性更好。
- 损伤脑组织可摄取和氧化乳酸,但代谢获益不一致,依赖氧化代谢保留、基线代谢状态、时机和剂量。
- 功能结局数据有限,可能带来认知和神经获益,但对有意义功能结局的影响仍不确定。
适用人群与场景
- 急性脑损伤患者,包括创伤性脑损伤、缺血性卒中和心脏骤停。
- 纳入临床前和临床研究,评估外源性乳酸钠给药。
研究设计与关键结果
- 共纳入12项临床前和12项临床研究。
- 在多数模型中,乳酸钠能有效降低颅内压,临床环境中至少与甘露醇或高渗盐水同样有效和安全。
- 部分研究报告乳酸钠相比传统渗透疗法全身血流动力学耐受性更好。
- 临床前和临床代谢数据显示损伤脑组织可摄取和氧化乳酸,但代谢获益不一致,取决于氧化代谢保留、基线代谢状态、时机和剂量。
- 功能结局数据有限,提示在实验和部分临床环境中可能有认知和神经获益。
- 结论认为乳酸钠是治疗颅内高压的有效方法,在特定条件下可能提供额外的代谢和全身优势;其对有意义功能结局的影响仍不确定,需针对性临床试验进一步研究。
证据类型、等级与局限
- 证据类型:系统评价,纳入临床前和临床研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 乳酸钠可作为急性脑损伤颅内高压治疗的选项之一,在临床环境中至少与甘露醇或高渗盐水同样有效且安全。
- 代谢获益不一致,可能依赖氧化代谢保留、基线代谢状态、时机和剂量,提示需改进患者选择并可能通过代谢监测指导治疗。
- 对有意义功能结局的影响仍不确定,需针对性临床试验进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sodium lactate–based solutions have been proposed as an alternative to conventional osmotic therapies for intracranial pressure (ICP) control in acute brain injury (ABI). Beyond their osmotic properties, lactate may also act as a cerebral metabolic substrate, although its effects appear context-dependent. The aim of this systematic review was to synthesize available data on lactate-based therapies in ABI, focusing on their effects on intracranial dynamics, cerebral metabolism and neurological outcomes to guide future clinical translation. METHODS: We performed a systematic review of preclinical and clinical studies evaluating exogenous sodium lactate administration in ABI, including traumatic brain injury, ischemic stroke, and cardiac arrest. Outcomes of interest included intracranial pressure control, cerebral metabolism, cerebral perfusion and oxygenation, systemic hemodynamics, safety, and functional recovery. RESULTS: Twelve preclinical and twelve clinical studies were included. Across most models, sodium lactate was effective in reducing ICP and at least as effective and safe as mannitol or hypertonic saline in clinical settings. Several studies reported improved systemic hemodynamic tolerance compared with conventional osmotherapy. Preclinical and clinical metabolic data demonstrated that lactate can be taken up and oxidized by the injured brain; however, metabolic benefits were inconsistent and appeared dependent on preserved oxidative metabolism, baseline metabolic status, timing, and dose. Functional outcome data were limited but suggested potential cognitive and neurological benefits in both experimental and selected clinical settings. CONCLUSIONS: Sodium lactate is an effective therapy for intracranial hypertension and may offer additional metabolic and systemic advantages in ABI patients under specific conditions. Its metabolic effects appear critically dependent on preserved oxidative capacity, highlighting the need for improved patient selection and the potential role of metabolic monitoring to guide therapy. The impact of lactate-based treatments on meaningful functional outcomes remains uncertain and warrants further investigation in targeted clinical trials.
参考来源
- Romero García N, Ruiz Zarco A, Ruiz Pacheco A, et al. Effects of lactate-based therapies on intracranial pressure and brain metabolism of patients with acute brain injury: a systematic review. Crit Care. 2026. PMID: 41896992. doi:10.1186/s13054-026-05973-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。